Expression of HOTAIR and PTGS2 as potential biomarkers in chronic myeloid leukemia patients in Brazil

Expression of HOTAIR and PTGS2 as potential biomarkers in chronic myeloid leukemia patients in Brazil

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm in which all the patients has the translocation ( ) that generates de BCR::ABL1 tyrosine kinase. Despite this disease possessing a good biomarker ( transcripts level) for diagnosis and prognosis, many studies has been performed t...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology Vol. 14; p. 1443346
Main Authors: Kubaski Benevides, Ana Paula, Marin, Anelis Maria, Wosniaki, Denise K, Oliveira, Rafaela Noga, Koerich, Gabriela Marino, Kusma, Bianca Nichele, Munhoz, Eduardo Cilião, Zanette, Dalila Luciola, Aoki, Mateus Nóbrega
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 10-10-2024
Subjects:
biomarkers
CML
HOTAIR
lncRNAs
Oncology
PTGS2
RNAseq
HOTAIR
lncRNAs
CML
PTGS2
RNAseq
biomarkers
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm in which all the patients has the translocation ( ) that generates de BCR::ABL1 tyrosine kinase. Despite this disease possessing a good biomarker ( transcripts level) for diagnosis and prognosis, many studies has been performed to investigate other molecules, such as the long noncoding RNAs (lncRNAs) and mRNAs, as potential biomarkers with the aim of predicting a change in levels and as an associated biomarker. A RNAseq was performed comparing 6 CML patients with high expression with 6 healthy control individuals, comprising the investigation cohort to investigate these molecules. To validate the results obtained by RNAseq, samples of 87 CML patients and 42 healthy controls were used in the validation cohort by RT-qPCR assays. The results showed lower expression of and in CML patients. The expression is inversely associated with expression in imatinib-treated CML patients, and to showing that CML patients with high expression showed reduced expression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Rui Liu, Xi’an Jiaotong University, China
Reviewed by: Apurva Patel, Gujarat Cancer & Research Institute, India
Edited by: Jixin Dong, University of Nebraska Medical Center, United States
Yanlong Shi, Nanjing Medical University, China
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2024.1443346